Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate® System (LAANTERN) Prospective Multi‑Center Registry
LAANTERN is a prospective, multi-center registry that will include data collection to evaluate procedural success, local control failure rate, and Quality of Life (QoL) in up to 1,000 patients and up to 50 sites. The study is currently enrolling eligible patients who would like to participate.
Study Device and Procedure:
The LAANTERN Registry will use the NeuroBlate System, a minimally invasive robotic laser thermotherapy tool that uses MRI-guided laser energy to ablate brain lesions.
With NeuroBlate, the surgeon attempts to ablate (destroy) lesions, or abnormal tissue, in the brain. Unlike traditional brain surgery, a procedure with the NeuroBlate System does not require a large opening in the skull. Instead, doctors create a small hole in the skull, about the diameter of a pencil. While the patient is in the MRI machine, the doctor guides a small laser device (probe) through the hole into the lesion. The probe delivers laser light energy that heats and destroys the affected tissue. Because the NeuroBlate System is MRI-guided, the neurosurgeon is able to visualize the specific area of the brain to be ablated. The precise nature of the procedure helps to lessen the likelihood of harm to nearby healthy tissue.1,2,3,4
Barrow Neurological Institute at Dignity Health St. Joseph’s Hospital & Medical Center
Site Principal Investigator: Kris Smith, MD
Contact: Odilette Trevizo, RN, CNRN
University of Louisville
Site Principal Investigator: Joseph Neimat, MD
Contact: Anna Williford
Norton Cancer Institute
Site Principal Investigator: David Sun, MD
Contact: Debbie Ritchey
University of Minnesota
Site Principal Investigator: Clark Chen, MD
Contact: Clark Chen, MD
Children’s Hospital St. Paul
St. Paul, MN
Site Principal Investigator: Joseph Petronio, MD
Contact: Katherine Ingram
New York University Langone Medical Center
New York, NY
Site Principal Investigator: Sylvia Kurz, MD
Contact 1: Malcolm Delara
Contact 2: Ankeeta Joshi
Ichan School of Medicine at Mount Sinai
New York, NY
Site Principal Investigator: Constantino Hadjipanayis, MD
Contact: Ryan Adams
SUNY Upstate Medical University
Site Principal Investigator: Zulma Tovar-Spinoza, MD
Contact: Sean Huckins
Duke University Medical Center
Site Principal Investigator: Peter Fecci, MD
Contact: Tammy O’Brien
Site Principal Investigator: Stephen Tatter, MD
Contact: Wendy Jenkins
University Hospitals Cleveland Medical Center
Site Principal Investigator: Andrew Sloan, MD
Contact: Karen Devine
Cleveland Clinic Foundation
Site Principal Investigator: Alireza Mohammadi, MD
Contact: Teresa Allison
Thomas Jefferson University
Site Principal Investigator: Kevin Judy, MD
Contact: Jaime Dougherty
University of Pittsburgh Medical Center
Site Principal Investigator: Taylor Abel, MD
Contact: Madison Remick
Monteris provides technology for neurosurgeons, which allows them to ablate (destroy with lethal heat) from the inside, brain lesions and brain tumors that may be difficult to approach via traditional methods. Technology includes the NeuroBlate System, AxiiiS, AtamA, and MiniBolt devices, which may be used together to apply the focused laser energy with little or no effect on surrounding healthy tissue. The NeuroBlate System provides clinicians a tool that offers near real-time control and MRI visualization of the therapy during laser ablation treatment.
All brain surgeries carry risk. Possible adverse events include, but are not limited to, hematoma, embolic events, edema, bleeding, cerebral spinal fluid (CSF) leakage, infection, unintended major tissue damage and permanent neurological deficits. Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events.
- Wilson TA, Karajannis MA, and Harter DH. Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int. 2014 May 8;5:64.
- Mohammadi AM and Schroeder JL. Laser interstitial thermal therapy in treatment of brain tumors – the NeuroBlate System. Expert Review of Medical Devices 2014 11:2, 109-119.
- Sloan AE, Ahluwalia MS, Valerio-Pascua J, et al. Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: clinical article. J Neurosurg. 2013 Jun;118(6):1202-19.
- Carpentier A, McNichols RJ, Stafford RJ, et al. Laser thermal therapy: real-time MRI-guided and computer- controlled procedures for metastatic brain tumors. Lasers Surg Med. 2011 Dec;43(10):943-50.